Therapeutic effect of reduced glutathione combined with compound glycyrrhizin on acute liver injury in children and its effect on inflammatory cytokines: A retrospective study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
UNLABELLED: Acute liver injury in children poses a serious threat to their health and life. The study aimed to evaluate the clinical efficacy of reduced glutathione (GSH) combined with compound glycyrrhizin (CG) in the treatment of acute liver injury in children and its effect on the inflammatory cytokines of body. METHODS: a retrospective study was conducted on 76 children with acute liver injury admitted to the Department of Pediatrics in Hefei Maternal and Child Health Hospital for treatment from January 2018 to June 2020, who was divided into a control group of 39 cases and a treatment group of 37 cases on the basis of different intervention methods. The control group was given intravenous infusion of 20 to 60 mg/kg GSH each time. On the basis of the control group, the treatment group was additionally given intravenous infusion of 1 to 2 mL/kg CG each time. The course of treatment lasted for 5 to 7 consecutive days, with 1 to 2 courses depending on the severity of the condition. The clinical efficacy, levels of liver functions and inflammatory cytokines, and incidence of adverse reactions between the 2 groups were observed and compared after treatment. RESULTS: after treatment, the total effective rate of the treatment group (94.59%) was significantly higher than that of the control group (76.92%) (P = .029), and the treatment group showed significantly lower levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) than the control group (P = .017, P = .014), but the levels of gamma-glutamyltranspeptidase (GGT) and albumin (ALB) between the 2 groups had no significant difference (P > .05). Compared with the control group, the levels of tumor necrosis factor α (TNF-α) and interleukin-17 (IL-17) in the treatment group significantly decreased (P = .000, P = .000). On the contrary, the level of interleukin-10 (IL-10) in the treatment group increased significantly after treatment (P = .000). There was no statistically significant difference in the incidence of adverse reactions between the 2 groups (P > .05). CONCLUSIONS: therapy with GSH combined with CG can effectively treat acute liver injury, reduce levels of ALT and AST, improve inflammatory response in children, and has reliable safety additionally.